摘要
目的探讨miR-21、miR-210在乳腺癌患者肿瘤组织及血浆中的含量,并进一步分析其在乳腺癌中的诊断及预后评价中的价值。方法收集31例乳腺癌患者肿瘤组织及36例癌旁组织,25例乳腺癌患者及21例健康者血浆。采用实时荧光定量PCR技术(real time fluorescence quantitative PCR,RTFQ PCR)检测miR-21、miR-210在乳腺癌患者肿瘤组织及血浆中的含量,应用受试者工作特征(receive operating characteristic,ROC)曲线分析其在乳腺癌中的诊断价值,通过Kaplan-Meier Plotter网站分析其与患者预后的关系。结果与癌旁正常组织比较,miR-21在乳腺癌肿瘤组织中的含量差异有统计学意义(P <0. 05),miR-210含量差异无统计学意义(P> 0. 05);与健康者血浆比较,miR-21、miR-210在乳腺癌患者血浆中的含量差异无统计学意义(P> 0. 05); miR-21在组织中ROC下面积为0. 695; miR-21高含量组患者生存时间明显低于miR-21低含量组(P <0. 05)。结论 miR-21在乳腺癌肿瘤组织中上调,可作为乳腺癌诊断与预后评价指标。
Objective To investigate the expression of miR-21 and miR-210 in tissues and plasma with breast cancer,further to analyze their value in the diagnosis and prognosis of breast cancer. Methods The expression of miR-21 and miR-210 in 31 tumor tissues and 36 normal tissues,25 tumor plasma samples and 21 healthy controls were detected by RTFQ PCR. We analyzed the diagnostic value of miRNA by receive operating characteristic( ROC) curve and the prognosis of patients by Kaplan-Meier Plotter website. Results The levels of miR-21 in tumor tissues were higher than that in normal tissues( P < 0. 05),whereas the levels of miR-210 were not( P > 0. 05). There were no significant differences between the tumor plasma samples and healthy controls( P > 0. 05). The area of miR-21 in tissues under the ROC curve was 0. 695. Kaplan-Meier Plotter reveled that higher miR-21 level was correlated with a shorter survival time( P < 0. 05). Conclusion miR-21 in breast cancer tissues is up-regulated,and it may be served as a novel marker of diagnosis and prognosis in the breast cancer.
引文
1 Harbeck N,Gnant M.Breast cancer[J].Lancet,2017,389(10074):1134-1150
2 Li S,Yang X,Yang J,et al.Serum microRNA-21 as a potential diagnostic biomarker for breast cancer:a systematic review and metaanalysis[J].Clin Exp Med,2016,16(1):29-35
3 Wang W,Xu X,Tian B,et al.The diagnostic value of serum tumor markers CEA,CA19-9 CA125,CA15-3,and TPS in metastatic breast cancer[J].Clin Chim Acta,2017,470(3):51-55
4 Madhavan D,Cuk K,Burwinkel B,et al.Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures[J].Front Genet,2013,4(10):116
5 Tang Y,Zhou X,Ji J,et al.High expression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer:a systemic review and meta-analysis[J].Int J Biol Markers,2015,30(9):e347-358
6 Campos-Parra AD,Mitznahuatl GC,Pedroza-Torres A,et al.Micro-RNAs as potential predictors of response to breast cancer systemic therapy:future clinical implications[J].Int J Mol Sci,2017,18(6):1182
7 Nazari SS,Mukherjee P.An overview of mammographic density and its association with breast cancer[J].Breast Cancer,2018,25(8):e347-358
8 Petrovic N.miR-21 might be involved in breast cancer promotion and invasion rather than in initial events of breast cancer development[J].Mol Diagn Ther,2016,20:97-110
9 Rask L,Balslev E,Skilde R,et al.Differential expression of miR-139,miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status[J].Cell Oncol(Dordr),2014,37:215-227
10 Han J,Jiang Y,Zhang C,et al.A novel panel of serum miR-21/miR-155/miR-365 as a potential diagnostic biomarker for breast cancer[J].Ann Surg Treat Res,2017,92:55-66
11 Tiberio P,Callari M,Angeloni V,et al.Challenges in using circulating miRNAs as cancer biomarkers[J].Biomed Res Int,2015,73(9):1479
12 Ulivi P,Zoli W.miRNAs as non-invasive biomarkers for lung cancer diagnosis[J].Molecules,2014,19:8220-8237
13 Zhu J,Zheng Z,Wang J,et al.Different miRNA expression profiles between human breast cancer tumors and serum[J].Front Genet,2014,5(8):e347-358:149
14 Witwer KW.Circulating microRNA biomarker studies:pitfalls and potential solutions[J].Clin Chem,2015,61(1):56-63
15 Hayes J,Peruzzi PP,Lawler S,et al.MicroRNAs in cancer:biomarkers,functions and therapy[J].Trends Mol Med,2014,20(8):460-469
